Phillip Dane Michaels, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dioxygenases | 1 | 2023 | 316 | 0.790 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 169 | 0.740 |
Why?
|
| Oral Ulcer | 1 | 2021 | 96 | 0.730 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2022 | 134 | 0.730 |
Why?
|
| Lymphoma, T-Cell | 1 | 2022 | 299 | 0.690 |
Why?
|
| Myeloproliferative Disorders | 1 | 2023 | 606 | 0.590 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 570 | 0.500 |
Why?
|
| Methotrexate | 1 | 2021 | 1728 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 578 | 0.470 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2023 | 3524 | 0.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1378 | 0.380 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 4153 | 0.310 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 3712 | 0.260 |
Why?
|
| Histiocytosis | 1 | 2022 | 40 | 0.210 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 345 | 0.190 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 1832 | 0.170 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2021 | 573 | 0.170 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2022 | 985 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 2649 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2022 | 1357 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 1271 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1660 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 21696 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2018 | 1063 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1813 | 0.110 |
Why?
|
| Calcifediol | 1 | 2012 | 166 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2020 | 2948 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2019 | 2073 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2019 | 1352 | 0.080 |
Why?
|
| Clone Cells | 2 | 2023 | 1692 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2023 | 7882 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 9647 | 0.070 |
Why?
|
| Prevalence | 1 | 2021 | 15221 | 0.060 |
Why?
|
| Humans | 11 | 2024 | 744366 | 0.060 |
Why?
|
| Prognosis | 1 | 2023 | 29060 | 0.050 |
Why?
|
| Mutation | 2 | 2023 | 29786 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 20824 | 0.030 |
Why?
|
| World Health Organization | 1 | 2022 | 1318 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2540 | 0.030 |
Why?
|
| Adolescent | 1 | 2022 | 85779 | 0.030 |
Why?
|
| RNA | 1 | 2024 | 2749 | 0.030 |
Why?
|
| Female | 3 | 2024 | 380193 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 77460 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57776 | 0.030 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2012 | 30 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 61 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4185 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2012 | 624 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2024 | 13035 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3595 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2012 | 799 | 0.020 |
Why?
|
| Drug Design | 1 | 2012 | 1076 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 3130 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10183 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 19905 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 9240 | 0.020 |
Why?
|
| Male | 1 | 2022 | 350115 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 10483 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 19233 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 11486 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13693 | 0.010 |
Why?
|